Affy Stock Slides 13 Percent on Weak Q2 as Banks Downgrade Shares and Temper Outlook | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Affymetrix were down approximately 13 percent, or $2.72, at $18.85 in mid-afternoon trading today after the company yesterday posted a $10.1 million net loss and a 4.7-percent decline in revenue for the second quarter.
 
The stock is currently trading at levels not seen since 2003.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.